126 related articles for article (PubMed ID: 35831333)
1. SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysis.
Samy A; Maher MA; Abdelsalam NA; Badr E
Sci Rep; 2022 Jul; 12(1):11934. PubMed ID: 35831333
[TBL] [Abstract][Full Text] [Related]
2. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches.
Ahmed FF; Reza MS; Sarker MS; Islam MS; Mosharaf MP; Hasan S; Mollah MNH
PLoS One; 2022; 17(4):e0266124. PubMed ID: 35390032
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches.
Hoque MN; Sarkar MMH; Khan MA; Hossain MA; Hasan MI; Rahman MH; Habib MA; Akter S; Banu TA; Goswami B; Jahan I; Nafisa T; Molla MMA; Soliman ME; Araf Y; Khan MS; Zheng C; Islam T
Front Immunol; 2022; 13():918692. PubMed ID: 36059456
[TBL] [Abstract][Full Text] [Related]
4. Lung disease network reveals impact of comorbidity on SARS-CoV-2 infection and opportunities of drug repurposing.
Das AB
BMC Med Genomics; 2021 Sep; 14(1):226. PubMed ID: 34535131
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.
MotieGhader H; Safavi E; Rezapour A; Amoodizaj FF; Iranifam RA
Sci Rep; 2021 Nov; 11(1):21872. PubMed ID: 34750486
[TBL] [Abstract][Full Text] [Related]
6. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
Ting CT; Chen BS
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
[TBL] [Abstract][Full Text] [Related]
7. Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mosharaf MP; Reza MS; Kibria MK; Ahmed FF; Kabir MH; Hasan S; Mollah MNH
Sci Rep; 2022 Mar; 12(1):4279. PubMed ID: 35277538
[TBL] [Abstract][Full Text] [Related]
8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
9. Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2.
Chen N; Zhang B; Deng L; Liang B; Ping J
Emerg Microbes Infect; 2022 Dec; 11(1):1371-1389. PubMed ID: 35476817
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
11. Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19).
Arora S; Singh P; Dohare R; Jha R; Ali Syed M
Gene; 2020 Dec; 762():145057. PubMed ID: 32805314
[TBL] [Abstract][Full Text] [Related]
12. Whole-Transcriptome RNA Sequencing Reveals Significant Differentially Expressed mRNAs, miRNAs, and lncRNAs and Related Regulating Biological Pathways in the Peripheral Blood of COVID-19 Patients.
Li CX; Chen J; Lv SK; Li JH; Li LL; Hu X
Mediators Inflamm; 2021; 2021():6635925. PubMed ID: 33833618
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
Liang H; Zhao L; Gong X; Hu M; Wang H
Clin Transl Sci; 2021 May; 14(3):1123-1132. PubMed ID: 33606912
[TBL] [Abstract][Full Text] [Related]
14. Differential microRNA expression in the peripheral blood from human patients with COVID-19.
Li C; Hu X; Li L; Li JH
J Clin Lab Anal; 2020 Oct; 34(10):e23590. PubMed ID: 32960473
[TBL] [Abstract][Full Text] [Related]
15. Human microRNA hsa-miR-15b-5p targets the RNA template component of the RNA-dependent RNA polymerase structure in severe acute respiratory syndrome coronavirus 2.
Sato A; Ogino Y; Tanuma SI; Uchiumi F
Nucleosides Nucleotides Nucleic Acids; 2021; 40(8):790-797. PubMed ID: 34263708
[TBL] [Abstract][Full Text] [Related]
16. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase.
Sokullu E; Pinard M; Gauthier MS; Coulombe B
Expert Opin Drug Discov; 2021 Aug; 16(8):881-895. PubMed ID: 33769912
[No Abstract] [Full Text] [Related]
19. Construction and Investigation of Competing Endogenous RNA Networks and Candidate Genes Involved in SARS-CoV-2 Infection.
Qi M; Liu B; Li S; Ni Z; Li F
Int J Gen Med; 2021; 14():6647-6659. PubMed ID: 34675627
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Husain A; Byrareddy SN
Chem Biol Interact; 2020 Nov; 331():109282. PubMed ID: 33031791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
